Strategic area of application
Human Medicine
Application market
Infectiology - Parasitology - Others
Activities
Therapeutics, Pharma or Biotech
Technologies
Antibodies - Protein - Peptide
Presentation of company's activity
In an environment where the globalization of trade accelerates the spread of epidemics and where the geopolitical context increases the risk of bioterrorist attacks, nations should be prepared to address various situations of public health & medical emergency. However, there is generally no real therapeutic option to fight acute symptoms arising from these neglected indications.
Fab’entech is a privately owned biopharmaceutical SME developing immunotherapies to address such situations of emergency.
Based on its horse F(ab’)2 platform, a fully-derisked technology in-licensed from Sanofi Pasteur, Fab’entech aims to provide therapeutic solutions in the fields of biodefense, drug intoxication and infectious disease.
Key features of company
After having developed Fabenflu(R), a product indicated for the treatment of avian influenza (H5N1) in human, Fab’entech is currently focusing on 3 products: a biodefense antidote developed in collaboration with the French army, a treatment for drug intoxication developed in a confidential indication, and an Ebola therapy developed with the support of the European Commission after having been identified by the WHO as the unique therapeutic solution in Europe in 2014.
Fab’entech is also member of public-private consortiums targeting emerging infectious diseases like Crimean-Congo Hemorrhagic Fever (CCHF) with the support of BPI France & Grand Lyon.
Skills and know-how
Fab’entech’s platform is used for the development and manufacturing of immunotherapies composed of highly purified F(ab’)2 fragments of horse specific polyclonal immunoglobulins.
This technology has been developed by Sanofi Pasteur, then in-licensed by Fab'entech.
Such platform having been fully-validated with the development of Fabenflu(R), Fab’entech can develop and manufacture, in a short period of time and for limited investments, new immunotherapies from high quality & security standards.
